Busulfan-fludarabine as myeloablative conditioning regimen in allogeneic stem cell transplantation: incidence of complications and outcome. A single-centre experience

被引：0
|
作者：
Parma, M. [1 ]
Pioltelli, P. [1 ]
Terruzzi, E. [1 ]
Bozzani, S. [1 ]
Pogliani, E. [1 ]
机构：
[1] Osped San Gerardo, Monza, Italy
来源：
BONE MARROW TRANSPLANTATION | 2012年 / 47卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S94 / S94
页数：1
相关论文
共 50 条
  • [41] Incidence of late-onset noninfectious pulmonary complications in allogeneic stem cell transplantation with non-myeloablative conditioning based on fludarabine/TBI or fludarabine/melphalan
    Zinke-Cerwenka, W.
    Scheidl, S.
    Eibl, M.
    Posch, U.
    Linkesch, W.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S295 - S295
  • [42] Once daily IV busulfan given with fludarabine in allogeneic stem cell transplantation conditioning: High vs low busulfan AUC does not alter toxicities or transplant outcome.
    Geddes, M
    Kangarloo, SB
    Naveed, F
    Chaudhry, AM
    Jeje, O
    Savoie, ML
    Bahlis, NJ
    Stewart, DA
    Brown, C
    Storek, J
    Quinlan, D
    Andersson, B
    Russell, JA
    BLOOD, 2005, 106 (11) : 501A - 501A
  • [43] Hemopoietic stem cell allogeneic transplantation (HSCT) using a reduced conditioning regimen:: A single centre experience.
    Scimè, R
    Cavallaro, AM
    Santoro, A
    Tringali, S
    Indovina, A
    Marcenò, R
    Pagano, A
    Polizzi, D
    Majolino, I
    BLOOD, 2000, 96 (11) : 357B - 357B
  • [44] MYELOABLATIVE CONDITIONING WITH FLUDARABINE AND (IV) BUSULFAN (F-BU4) FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELODYSPLASIC SYNDROMES
    Talbi, A.
    Nacer, R. Ahmed
    Benakli, M.
    Mehdid, F.
    Belhadj, R.
    Rahmoune, N.
    Baazizi, M.
    Ouali, D. Ait
    Bouarab, H.
    Harieche, F.
    Hamladji, R. M.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S186 - S187
  • [45] Non-myeloablative allogeneic stem cell transplantation in patients with high-risk lymphoma:: a single-centre experience
    Console, G.
    Messina, G.
    Martino, M.
    Irrera, G.
    Pucci, G.
    Massara, E.
    Moscato, T.
    Fedele, R.
    Cuzzola, M.
    Gatto, F.
    Spiniello, E.
    Meliado, A.
    Rigolino, C.
    Dattola, A.
    Callea, I.
    Pontari, A.
    Monteleone, R.
    Stelitano, C.
    Callea, V.
    Mamone, D.
    Kropp, M.
    Molica, S.
    Abbadessa, A.
    Iacopino, P.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S247 - S247
  • [46] Treosulfan/fludarabine - a low toxicity but myeloablative conditioning for allogeneic hematopoietic stem cell transplantation
    Holowiecki, J
    Giebel, S
    Wojnar, J
    Krawczyk-Kulis, M
    Wylezol, I
    Kruzel, T
    Markiewicz, M
    BLOOD, 2004, 104 (11) : 292A - 292A
  • [47] Outcome following second allogeneic hematopoietic cell transplantation: a single-centre experience
    Aljasem, H.
    Messner, H.
    Lipton, J.
    Kim, D.
    Viswabandya, A.
    Thyagu, S.
    Deotare, U.
    Michelis, F.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S302 - S303
  • [48] The Efficacy and Safety of Busulfan Dose Intensity with Fludarabine Conditioning Regimen for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. A Single Center Experience
    Massoud, Radwan
    Heller, Raban
    Moukalled, Nour
    Matar, Charbel
    Haffar, Basel
    Bazarbachi, Ali
    El-Cheikh, Jean
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S310 - S311
  • [49] Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience
    J L Piñana
    R Martino
    P Barba
    N Margall
    M C Roig
    D Valcárcel
    J Sierra
    N Rabella
    Bone Marrow Transplantation, 2010, 45 : 534 - 542
  • [50] Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience
    Pinana, J. L.
    Martino, R.
    Barba, P.
    Margall, N.
    Roig, M. C.
    Valcarcel, D.
    Sierra, J.
    Rabella, N.
    BONE MARROW TRANSPLANTATION, 2010, 45 (03) : 534 - 542
12345